25 Citations (Scopus)

Abstract

Background Observational reports have linked vitamin D with chronic urticaria, yet no randomized controlled trial has been conducted. Objective To determine whether high-dose vitamin D supplementation would decrease Urticaria Symptom Severity (USS) scores and medication burden in patients with chronic urticaria. Methods In a prospective, double-blinded, single-center study, 42 subjects with chronic urticaria were randomized to high (4,000 IU/d) or low (600 IU/d) vitamin D3 supplementation for 12 weeks. All subjects were provided with a standardized triple-drug therapy (cetirizine, ranitidine, and montelukast) and a written action plan. Data on USS scores, medication use, blood for 25-hydroxyvitamin D, and safety measurements were collected. Results Triple-drug therapy decreased total USS scores by 33% in the first week. There was a further significant decrease (40%) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12. Compared with low treatment, the high treatment group demonstrated a trend (P =.052) toward lower total USS scores at week 12, which was driven by significant decreases in body distribution and number of days with hives. Beneficial trends for sleep quality and pruritus scores were observed with high vitamin D3. Serum 25-hydroxyvitamin D levels increased with high vitamin D3 supplementation, but there was no correlation between 25-hydroxyvitamin D levels and USS scores. There was no difference in allergy medication use between groups. No adverse events occurred. Conclusion Add-on therapy with high-dose vitamin D3 (4,000 IU/d) could be considered a safe and potentially beneficial immunomodulator in patients with chronic urticaria. Trial Registration clinicaltrials.gov Identifier: NCT01371877.

Original languageEnglish (US)
Pages (from-to)376-382
Number of pages7
JournalAnnals of Allergy, Asthma and Immunology
Volume112
Issue number4
DOIs
StatePublished - Apr 2014

Fingerprint

Cholecalciferol
Urticaria
Therapeutics
montelukast
Vitamin D
Cetirizine
Drug Therapy
Ranitidine
Immunologic Factors
Pruritus
Sleep
Hypersensitivity
Randomized Controlled Trials
Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Beneficial role for supplemental vitamin D3 treatment in chronic urticaria : A randomized study. / Rorie, Andy; Goldner, Whitney S; Lyden, Elizabeth; Poole, Jill A.

In: Annals of Allergy, Asthma and Immunology, Vol. 112, No. 4, 04.2014, p. 376-382.

Research output: Contribution to journalArticle

@article{251e29abdbee4c90b4c0695052be6307,
title = "Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: A randomized study",
abstract = "Background Observational reports have linked vitamin D with chronic urticaria, yet no randomized controlled trial has been conducted. Objective To determine whether high-dose vitamin D supplementation would decrease Urticaria Symptom Severity (USS) scores and medication burden in patients with chronic urticaria. Methods In a prospective, double-blinded, single-center study, 42 subjects with chronic urticaria were randomized to high (4,000 IU/d) or low (600 IU/d) vitamin D3 supplementation for 12 weeks. All subjects were provided with a standardized triple-drug therapy (cetirizine, ranitidine, and montelukast) and a written action plan. Data on USS scores, medication use, blood for 25-hydroxyvitamin D, and safety measurements were collected. Results Triple-drug therapy decreased total USS scores by 33{\%} in the first week. There was a further significant decrease (40{\%}) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12. Compared with low treatment, the high treatment group demonstrated a trend (P =.052) toward lower total USS scores at week 12, which was driven by significant decreases in body distribution and number of days with hives. Beneficial trends for sleep quality and pruritus scores were observed with high vitamin D3. Serum 25-hydroxyvitamin D levels increased with high vitamin D3 supplementation, but there was no correlation between 25-hydroxyvitamin D levels and USS scores. There was no difference in allergy medication use between groups. No adverse events occurred. Conclusion Add-on therapy with high-dose vitamin D3 (4,000 IU/d) could be considered a safe and potentially beneficial immunomodulator in patients with chronic urticaria. Trial Registration clinicaltrials.gov Identifier: NCT01371877.",
author = "Andy Rorie and Goldner, {Whitney S} and Elizabeth Lyden and Poole, {Jill A}",
year = "2014",
month = "4",
doi = "10.1016/j.anai.2014.01.010",
language = "English (US)",
volume = "112",
pages = "376--382",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "4",

}

TY - JOUR

T1 - Beneficial role for supplemental vitamin D3 treatment in chronic urticaria

T2 - A randomized study

AU - Rorie, Andy

AU - Goldner, Whitney S

AU - Lyden, Elizabeth

AU - Poole, Jill A

PY - 2014/4

Y1 - 2014/4

N2 - Background Observational reports have linked vitamin D with chronic urticaria, yet no randomized controlled trial has been conducted. Objective To determine whether high-dose vitamin D supplementation would decrease Urticaria Symptom Severity (USS) scores and medication burden in patients with chronic urticaria. Methods In a prospective, double-blinded, single-center study, 42 subjects with chronic urticaria were randomized to high (4,000 IU/d) or low (600 IU/d) vitamin D3 supplementation for 12 weeks. All subjects were provided with a standardized triple-drug therapy (cetirizine, ranitidine, and montelukast) and a written action plan. Data on USS scores, medication use, blood for 25-hydroxyvitamin D, and safety measurements were collected. Results Triple-drug therapy decreased total USS scores by 33% in the first week. There was a further significant decrease (40%) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12. Compared with low treatment, the high treatment group demonstrated a trend (P =.052) toward lower total USS scores at week 12, which was driven by significant decreases in body distribution and number of days with hives. Beneficial trends for sleep quality and pruritus scores were observed with high vitamin D3. Serum 25-hydroxyvitamin D levels increased with high vitamin D3 supplementation, but there was no correlation between 25-hydroxyvitamin D levels and USS scores. There was no difference in allergy medication use between groups. No adverse events occurred. Conclusion Add-on therapy with high-dose vitamin D3 (4,000 IU/d) could be considered a safe and potentially beneficial immunomodulator in patients with chronic urticaria. Trial Registration clinicaltrials.gov Identifier: NCT01371877.

AB - Background Observational reports have linked vitamin D with chronic urticaria, yet no randomized controlled trial has been conducted. Objective To determine whether high-dose vitamin D supplementation would decrease Urticaria Symptom Severity (USS) scores and medication burden in patients with chronic urticaria. Methods In a prospective, double-blinded, single-center study, 42 subjects with chronic urticaria were randomized to high (4,000 IU/d) or low (600 IU/d) vitamin D3 supplementation for 12 weeks. All subjects were provided with a standardized triple-drug therapy (cetirizine, ranitidine, and montelukast) and a written action plan. Data on USS scores, medication use, blood for 25-hydroxyvitamin D, and safety measurements were collected. Results Triple-drug therapy decreased total USS scores by 33% in the first week. There was a further significant decrease (40%) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12. Compared with low treatment, the high treatment group demonstrated a trend (P =.052) toward lower total USS scores at week 12, which was driven by significant decreases in body distribution and number of days with hives. Beneficial trends for sleep quality and pruritus scores were observed with high vitamin D3. Serum 25-hydroxyvitamin D levels increased with high vitamin D3 supplementation, but there was no correlation between 25-hydroxyvitamin D levels and USS scores. There was no difference in allergy medication use between groups. No adverse events occurred. Conclusion Add-on therapy with high-dose vitamin D3 (4,000 IU/d) could be considered a safe and potentially beneficial immunomodulator in patients with chronic urticaria. Trial Registration clinicaltrials.gov Identifier: NCT01371877.

UR - http://www.scopus.com/inward/record.url?scp=84897384941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897384941&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2014.01.010

DO - 10.1016/j.anai.2014.01.010

M3 - Article

C2 - 24507460

AN - SCOPUS:84897384941

VL - 112

SP - 376

EP - 382

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 4

ER -